The FDA agreed that the Company’s existing clinical data package, including results from the Phase 3 SHIELD II trial, appears adequate to support NDA submission and review. The FDA also agreed to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback